Abbott Laboratories (ABT)vsBeta Bionics, Inc. Common Stock (BBNX)
ABT
Abbott Laboratories
$108.03
+0.68%
HEALTHCARE · Cap: $177.07B
BBNX
Beta Bionics, Inc. Common Stock
$15.17
-3.99%
HEALTHCARE · Cap: $785.18M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 42159% more annual revenue ($46.59B vs $110.24M). ABT leads profitability with a 11.7% profit margin vs -60.3%. ABT earns a higher WallStSmart Score of 52/100 (C-).
ABT
Buy52
out of 100
Grade: C-
BBNX
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.2%
Fair Value
$73.35
Current Price
$108.03
$34.68 premium
Intrinsic value data unavailable for BBNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Revenue surging 56.6% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -24.5% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : BBNX
The strongest argument for BBNX centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 56.6% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : BBNX
The primary concerns for BBNX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABT profiles as a value stock while BBNX is a hypergrowth play — different risk/reward profiles.
BBNX is growing revenue faster at 56.6% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABT scores higher overall (52/100 vs 36/100) and 13.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Beta Bionics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?